Phase I study of AZD6738, an inhibitor of ataxia telangiectasia Rad3-related (ATR), in combination with olaparib or durvalumab in patients (pts) with advanced solid cancers
dc.contributor.author | Krebs, Matthew G | |
dc.contributor.author | Lopez, J | |
dc.contributor.author | El-Khoueiry, A | |
dc.contributor.author | Bang, Y | |
dc.contributor.author | Postel-Vinay, S | |
dc.contributor.author | Abida, W | |
dc.contributor.author | Carter, Louise | |
dc.contributor.author | Xu, W | |
dc.contributor.author | Im, S | |
dc.contributor.author | Pierce, A | |
dc.contributor.author | Frewer, P | |
dc.contributor.author | Berges, A | |
dc.contributor.author | Cheung, A | |
dc.contributor.author | Stephens, C | |
dc.contributor.author | Felicetti, B | |
dc.contributor.author | Dean, E | |
dc.contributor.author | Hollingsworth, S | |
dc.date.accessioned | 2019-09-11T09:09:18Z | |
dc.date.available | 2019-09-11T09:09:18Z | |
dc.date.issued | 2018 | en |
dc.identifier.citation | Krebs MG, Lopez J, El-Khoueiry A, Bang Y-J, Postel-Vinay S, Abida W, et al. Phase I study of AZD6738, an inhibitor of ataxia telangiectasia Rad3-related (ATR), in combination with olaparib or durvalumab in patients (pts) with advanced solid cancers. Cancer Res. 2018;78(13). | en |
dc.identifier.doi | 10.1158/1538-7445.AM2018-CT026 | en |
dc.identifier.uri | http://hdl.handle.net/10541/622034 | |
dc.language.iso | en | en |
dc.relation.url | https://dx.doi.org/10.1158/1538-7445.AM2018-CT026 | en |
dc.title | Phase I study of AZD6738, an inhibitor of ataxia telangiectasia Rad3-related (ATR), in combination with olaparib or durvalumab in patients (pts) with advanced solid cancers | en |
dc.type | Meetings and Proceedings | en |
dc.contributor.department | The Christie NHS Foundation Trust and The University of Manchester Manchester | en |
dc.identifier.journal | Cancer Research | en |
dc.description.note | en] |